Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection

Journal of Infectious Diseases

Volumn 191, Issue 5, 2005, Pages 654-665

  Flynn, N M ^a   Forthal, D N ^a   Harro, C D ^a   Judson, F N ^a   Mayer, K H ^a   Para, M F ^a   Gurwith, Marc ^a  

^a VaxGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIDSVAX B; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; RECOMBINANT GLYCOPROTEIN GP 120 VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDEMA; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SKIN INDURATION; SUBCUTANEOUS NODULE; VIRUS LOAD;

ADOLESCENT; ADULT; AIDS VACCINES; DISEASE PROGRESSION; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RISK-TAKING; TIME FACTORS; VACCINES, SYNTHETIC;

EID: 13944254982     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428404     Document Type: Article

References (51)

1. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 2000; 355:2061-6.
2. Spearman P. HIV vaccine development: lessons from the past and promise for the future. Curr HIV Res 2003; 1:101-20.
3. Nathanson N, Mathieson BJ. Biological considerations in the development of a human immunodeficiency virus vaccine. J Infect Dis 2000; 182:579-89.
4. Fowke KR, Nagelkerke NJD, Kimani J, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348:1347-51.
5. + cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 1999; 96:1030-5.
6. Jennes W, Vuylsteke B, Borget M-Y, et al. HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Côte d'Ivoire. J Infect Dis 2003; 187:1053-63.
7. Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998; 351:14-8.
8. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
9. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
10. Zinkernagel RM. Are HIV-specific CTL responses salutary or pathogenic? Curr Opin Immunol 1995; 7:462-70.
11. McMichael AJ, Hanke T. HIV vaccines 1983-2003. Nat Med 2003; 9: 874-80.
12. Berman PW, Gregory TJ, Riddle L, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990; 345:622-5.
13. el Amad Z, Murthy KK, Higgins K, et al. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2. AIDS 1995; 9:1313-22.
14. Berman PW, Murthy KK, Wrin T, et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type I. J Infect Dis 1996; 173: 52-9.
15. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 1994; 272:475-80.
16. Pitisuttithum P, Berman PW, Phonrat B, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004; 37:1160-5.
17. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S325-31.
18. Herman PW, Huang W, Riddle L, et al. Development of bivalent (B/E) vaccines able to neutralize CCRS-dependent viruses from the United States and Thailand. Virology 1999; 265:1-9.
19. Harro CD, Judson FN, Gorse GJ, et al. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2004; 37:1385-92.
20. Francis DP, Heyward WL, Popovic V, et al. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS 2003; 17:147-56.
21. Peterson ML, Good JW, Zaharias EM, et al. Development of a novel assay to measure antigen-specific immune responses to multivalent vaccines for HIV-1 [abstract 769]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
22. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-77 (in this issue).
23. Allison PD. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute, 1995.
24. Bristol DR. p-value adjustments for subgroup analyses. J Biopharm Stat 1997; 7:313-21/323-31.
25. Pollard KS, van der Laan MJ. Choice of a null distribution in resampling-based multiple testing. J Statist Plann Inference 2004; 125:85-100.
26. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51:524-32.
27. Choopanya K, Tappero JW, Pitisuttithum P, et al. Preliminary results of a phase III HIV vaccine efficacy trial among injecting drug users in Thailand [abstract ThOrA1427]. In: Program and abstracts of the XV International AIDS Conference 2004 (Bangkok, Thailand). Bangkok, Thailand: Clung Wicha Press, 2004.
28. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19:500-12.
29. Burke DS. Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk? Perspect Biol Med 1992; 35:511-30.
30. King RT. FDA allows large-scale trial of AIDS vaccine. Wall Street Journal. 3 June 1998:1.
31. Chesney MA, Chambers D, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:266-71.
32. Bloom BR. The highest attainable standard: ethical issues in AIDS vaccines. Science 1998; 279:186-8.
33. Ackers M-L, Parekh B, Evans TG, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis 2003; 187:879-86.
34. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 1652-61.
35. Whitacre CC, Reingold SC, O'Looney PA, et al. Biomedicine: a gender gap in autoimmunity. Science 1999; 283:1277-8.
36. Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37:590-9.
37. Schacker T, Zeh J, Hu HL, Hill J, Corey L. Frequency of symptomatic and asymptomatic HSV-2 reactivations among HIV-infected men. J Infect Dis 1998; 178:1616-22.
38. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52.
39. Xiang J, Wunschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345:707-14.
40. George SL, Wunschmann S, McCoy J, Xiang J, Stapleton JT. Interactions between GB virus type C and HIV. Curr Infect Dis Rep 2002; 4: 550-8.
41. Williams CF, Klinzman D, Yamashita TE, et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004; 350: 981-90.
42. Pomerantz RJ, Nunnari G. HIV and GB virus C: can two viruses be better than one? N Engl J Med 2004; 350:963-5.
43. Dawson GJ, Schlauder GG, Pilot-Matias TJ, et al. Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction. J Med Virol 1996; 50:97-103.
44. Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355:1064-9.
45. Klinman DM, Kamstrup S, Verthelyi D, et al. Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Springer Semin Immunopathol 2000; 22:173-83.
46. Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999; 17:2517-27.
47. Frank FM, Petray PB, Cazorla SI, Munoz MC, Corral RS, Malchiodi EL. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxy-nucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 2003; 22:77-86.
48. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 2002; 168:1659-63.
49. Nabel GJ. Challenges and opportunities of development of an AIDS vaccine. Nature 2001; 410:1002-6.
50. Schultz AM, Bradac JA. The HIV vaccine pipeline, from preclinical to phase III. AIDS 2001; 15(Suppl 5):S147-58.
51. Nitayaphan S, Pitisuttithum P, de Souza M, et al. Safety and immunogenicity of live recombinant ALVAC-HIV (vCP1521) priming with AIDSVAX B/E gp120 boosting in Thai HIV-negative adults (abstract WePeB6049). In: Program and abstracts of the XIV International AIDS Conference 2002 (Barcelona, Spain). Barcelona, Spain: Prous Science, 2002.